Rating- neutral; Pharma sector- Poised for strong growth in Q1FY24
时间:2024-06-02 06:06:12 阅读(143)
We anticipate a positive performance from our pharmaceutical sector coverage in Q1FY24, driven by improved sales in the US market and strong performance across most branded markets. As the cost pressures gradually ease, we expect to see a robust y-o-y Ebitda growth of 22% (excluding BIOS and Mankind). In the hospital segment, we project a relatively stable performance compared to the previous quarter, with occupancy trends gradually returning to pre-Covid levels. For diagnostic companies, we anticipate a slight increase in non-Covid realisations per patient on a quarterly basis, supported by price hikes and higher volumes of non-Covid tests. Our top picks in the pharma sector are Sun Pharma (SUNP), Mankind, and Cipla. Although recent price increases may limit short-term upside, we maintain a positive outlook on APHS, Rainbow, and KIMS in the healthcare services sector.
Pharma: Improved US, healthy branded markets, yoy margin expansion in store
Hospitals: Steady quarter in store We expect a sequentially steady performance for the India-based hospitals, with lower occupancies being offset by higher ARPOB. For hospitals, we forecast a topline growth of 15% y-o-y in Q1FY24. Overall, we expect an Ebitda growth of 20% y-o-y for our hospitals.
Diagnostics: We expect an uptick in B2C sales growth
Regarding the diagnostic firms, we anticipate a slight increase in non-Covid revenue per patient q-o-q, supported by price adjustments and higher volumes of non-Covid tests. We have factored in a y-o-y growth of 8-12% in non-Covid sales for DLPL and METROHL. We expect a decrease in Covid-related sales for both compared to the last quarter. In Q1FY24, we project a 20% q-o-q Ebitda growth rate for DLPL and a 2% q-o-q growth rate for METROHL. The lower growth rate for METROHL is due to the loss of the NACO contract, which accounted for 4-5% of sales, starting from February 2023.
猜你喜欢
- Sanjiv Bhasin sees Nifty hitting new high in FY23; bullish on these 2 private bank stocks - IIFL INTERVIEW
- Buy these two stocks for near-term gains, charts show strength; Nifty needs to hold above 17550, buy on dips
- Rupee rises 33 paise to 81
- Sailing into success- Reflecting on a year of smart consumer-driven campaigns in our digitally savvy world
- Gold outlook- MCX gold sentiment shifts to bullish trend; buy yellow metal for dip near Rs 50700
- Cannes 2023- Indian celebrities who dazzled the Red Carpet with glitz & glamour! See Photos
- Rupee rises 8 paise to end at 81
- Gold Price Today, 11 August 2022- MCX Gold prices may trade in Rs 51800-52250 range, support at Rs 51800
- Global Markets- Stocks slide, dollar holds ground as US rate hike looms